pharmaceutical-technology.com
Lilly gains US FDA approval for Omvoh to treat Crohn’s disease
FDA approval means mirikizumab (Omvoh) is now an available biologic option in the US for adults with moderately to severely active Crohn’s disease, especially for people who did not respond to standard treatments. It may affect treatment discussions and choices for patients and clinicians.
Adults with moderate-to-severe Crohn’s disease, patients considering or on biologic therapy, gastroenterologists and clinic teams, and researchers tracking IL-23–targeted therapies.
What To Know
The FDA has approved Omvoh (mirikizumab-mrkz) for treatment of moderately to severely active Crohn’s disease in adults, based on positive Phase III VIVID-1 trial results showing clinical remission and endoscopic response at one year.
The article notes 53% of treated subjects achieved clinical remission and 46% showed visible healing of the intestinal lining versus placebo. The therapy targets IL-23p19 and was previously approved for ulcerative colitis; regulatory submissions are underway in other regions and the EMA CHMP recommended approval in December 2024.
What this means: Omvoh is an IL-23p19-targeting biologic now approved in the US for Crohn’s disease, adding another treatment option for adults with moderate-to-severe disease, including patients who did not respond to or tolerated standard therapies.
The article references one-year Phase III efficacy and ongoing open-label extension safety/efficacy follow-up (VIVID-2) through three years.
Practical points: This is a regulatory approval report — it does not provide prescribing guidance, comparative effectiveness versus other biologics, safety detail beyond a general statement that safety in CD was consistent with UC experience, or cost/coverage information.
Patients should discuss with their gastroenterologist whether this drug is appropriate for them and wait for local regulatory/coverage decisions where relevant. Source notes: classification and statements above are drawn directly from the Pharmaceutical-Technology article reporting the FDA decision and trial results.
This article reports a regulatory approval based on Phase III trial endpoints at one year and mentions ongoing longer-term follow-up. It does not replace clinical guidance, does not present head-to-head comparisons with other drugs, and lacks detailed safety and access/cost information.
